Chemical: Drug
quinidine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for quinidine and CYP2D6
  2. FDA Label for dextromethorphan,quinidine and CYP2D6
  3. EMA Label for dextromethorphan,quinidine and CYP2D6




PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for quinidine

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1805128 NC_000021.8:g.35821680C>T, NC_000021.9:g.34449382C>T, NG_009091.1:g.66934G>A, NM_000219.3:c.253G>A, NM_000219.5:c.253G>A, NM_001127668.3:c.253G>A, NM_001127669.3:c.253G>A, NM_001127670.1:c.253G>A, NM_001127670.3:c.253G>A, NM_001270402.2:c.253G>A, NM_001270403.2:c.253G>A, NM_001270404.2:c.253G>A, NM_001270405.2:c.253G>A, NP_000210.2:p.Asp85Asn, NP_001121140.1:p.Asp85Asn, NP_001121141.1:p.Asp85Asn, NP_001121142.1:p.Asp85Asn, NP_001257331.1:p.Asp85Asn, NP_001257332.1:p.Asp85Asn, NP_001257333.1:p.Asp85Asn, NP_001257334.1:p.Asp85Asn, XM_005260972.1:c.316G>A, XM_005260973.1:c.13+6004G>A, XM_011529555.1:c.13+6004G>A, XM_011529557.1:c.279+9272G>A, XP_005261029.1:p.Asp106Asn, rs17173507, rs52820407
C > T
SNP
D85N
No VIP available No Clinical Annotations available VA
rs2276314 NC_000018.10:g.35977503A>G, NC_000018.9:g.33557466A>G, NM_001201474.1:c.130A>G, NM_001201475.1:c.130A>G, NM_001201476.1:c.301-1332A>G, NM_031446.4:c.394A>G, NP_001188403.1:p.Thr44Ala, NP_001188404.1:p.Thr44Ala, NP_113634.3:p.Thr132Ala, XM_005258364.1:c.412A>G, XM_005258364.3:c.412A>G, XP_005258421.1:p.Thr138Ala, rs17845782, rs17858743, rs52824020, rs59707726
A > G
SNP
T44A
No VIP available No Clinical Annotations available VA
rs7295250 NC_000012.11:g.2776943T>C, NC_000012.12:g.2667777T>C, NG_008801.2:g.701992T>C, NM_000719.6:c.4623+995T>C, NM_001129827.1:c.4767+995T>C, NM_001129829.1:c.4689+995T>C, NM_001129830.1:c.4623+995T>C, NM_001129830.2:c.4623+995T>C, NM_001129831.1:c.4707+995T>C, NM_001129832.1:c.4683+995T>C, NM_001129833.1:c.4623+995T>C, NM_001129834.1:c.4623+995T>C, NM_001129835.1:c.4623+995T>C, NM_001129836.1:c.4674+995T>C, NM_001129837.1:c.4590+995T>C, NM_001129838.1:c.4590+995T>C, NM_001129839.1:c.4584+995T>C, NM_001129840.1:c.4623+995T>C, NM_001129841.1:c.4623+995T>C, NM_001129842.1:c.4623+995T>C, NM_001129843.1:c.4623+995T>C, NM_001129844.1:c.4614+995T>C, NM_001129846.1:c.4590+995T>C, NM_001167623.1:c.4623+995T>C, NM_001167624.2:c.4623+995T>C, NM_001167625.1:c.4590+995T>C, NM_199460.3:c.4767+995T>C, XM_005253765.1:c.4917+995T>C, XM_005253766.1:c.4776+995T>C, XM_005253767.1:c.4599+995T>C, XM_005253768.1:c.4776+995T>C, XM_005253769.1:c.4698+995T>C, XM_005253770.1:c.4632+995T>C, XM_005253771.1:c.4632+995T>C, XM_005253772.1:c.4716+995T>C, XM_005253773.1:c.4692+995T>C, XM_005253774.1:c.4632+995T>C, XM_005253775.1:c.4632+995T>C, XM_005253776.1:c.4632+995T>C, XM_005253777.1:c.4683+995T>C, XM_005253778.1:c.4599+995T>C, XM_005253779.1:c.4599+995T>C, XM_005253780.1:c.4593+995T>C, XM_005253781.1:c.4632+995T>C, XM_005253782.1:c.4632+995T>C, XM_005253783.1:c.4632+995T>C, XM_005253784.1:c.4632+995T>C, XM_005253785.1:c.4632+995T>C, XM_005253786.1:c.4623+995T>C, XM_005253787.1:c.4599+995T>C, XM_005253788.1:c.2529+995T>C, XM_006719017.1:c.4713+995T>C, XM_011521017.1:c.3867+995T>C, XM_011521018.1:c.3312+995T>C, XM_011521019.1:c.1422+995T>C, XM_011521020.1:c.4788+995T>C, XM_011521021.1:c.4623+995T>C, XM_011521022.1:c.4623+995T>C, XM_011521023.1:c.4698+995T>C, rs17761221, rs60758963
T > C
SNP
No VIP available No Clinical Annotations available VA
rs767531 NC_000018.10:g.35777904T>G, NC_000018.9:g.33357868T>G, rs386612419, rs57916855
T > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Quinidine Gluconate
  • Quinidine Sulfate
Trade Names
  • Apo-Quinidine
  • Biquin Durules
  • Cardioquin
  • Chinidin
  • Cin-Quin
  • Coccinine
  • Conchinin
  • Conchinine
  • Conquinine
  • Duraquin
  • Kinidin
  • Novoquinidin
  • Pitayin
  • Pitayine
  • Quin-Release
  • Quinact
  • Quinaglute
  • Quinaglute Dura-Tabs
  • Quinalan
  • Quinate
  • Quinatime
  • Quindine
  • Quinicardine
  • Quinidex
  • Quinidex Extentabs
  • Quinora
Brand Mixture Names

PharmGKB Accession Id

PA451209

Type(s):

Drug

Description

An optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.

Source: Drug Bank

Indication

For the treatment of ventricular pre-excitation and cardiac dysrhythmias

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Quinidine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Quinidine may also act on the slow inward calcium current (ICa), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito.

Source: Drug Bank

Pharmacology

Quinidine, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation.

Source: Drug Bank

Food Interaction

Preferably take on an ampty stomach.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Protein Binding

80-88%

Source: Drug Bank

Half-Life

6-8 hours

Source: Drug Bank

Clearance

Source: Drug Bank

Route of Elimination

When the urine pH is less than 7, about 20% of administered quinidine appears unchanged in the urine, but this fraction drops to as little as 5% when the urine is more alkaline.

Source: Drug Bank

Volume of Distribution

Source: Drug Bank

Chemical Properties

Chemical Formula

C20H24N2O2

Source: Drug Bank

Isomeric SMILES

COc1ccc2c(c1)c(ccn2)[C@@H]([C@@H]3CC4CCN3C[C@H]4C=C)O

Source: OpenEye

Canonical SMILES

COC1=CC2=C(C=CN=C2C=C1)[C@H](O)[C@H]

Source: Drug Bank

Average Molecular Weight

324.4168

Source: Drug Bank

Monoisotopic Molecular Weight

324.183778022

Source: Drug Bank

SMILES

[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1

Source: Drug Bank

InChI String

InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ABCB1 (source: Drug Bank )
KCNH2 (source: Drug Bank )
KCNK1 (source: Drug Bank )
KCNK6 (source: Drug Bank )
ORM1 (source: Drug Bank )
SCN5A (source: Drug Bank )

Curated Information ?

EvidenceDrug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
warfarin

Drug Interactions

Interaction Description
amiloride - quinidine Decreases the antiarrhythmic effect of quinidine (source: Drug Bank )
amiloride - quinidine Decreases the antiarrhythmic effect of quinidine (source: Drug Bank )
amiloride - quinidine Decreases the antiarrhythmic effect of quinidine (source: Drug Bank )
aminophylline - quinidine The barbiturate, quinidine barbiturate, decreases the effect of aminophylline. (source: Drug Bank )
amiodarone - quinidine Increases the effect of quinidine (source: Drug Bank )
amiodarone - quinidine Increases the effect of qiunidine (source: Drug Bank )
amiodarone - quinidine Increases the effect of qiunidine (source: Drug Bank )
amitriptyline - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
amitriptyline - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
amitriptyline - quinidine Quinidine barbiturate increases the effect of tricyclic antidepressant, amitriptyline. (source: Drug Bank )
aripiprazole - quinidine Quinidine increases the effect and toxicity of aripiprazole (source: Drug Bank )
aripiprazole - quinidine Quinidine increases the effect and toxicity of aripiprazole (source: Drug Bank )
aripiprazole - quinidine Quinidine increases the effect and toxicity of aripiprazole (source: Drug Bank )
atazanavir - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
atazanavir - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
atomoxetine - quinidine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank )
betamethasone - quinidine The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone. (source: Drug Bank )
bromazepam - quinidine Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if quinidine is initiated, discontinued or dose changed. Dosage adjustments may be required. (source: Drug Bank )
cimetidine - quinidine Increases the effect of quinidine (source: Drug Bank )
cimetidine - quinidine Increases the effect of quinidine (source: Drug Bank )
cimetidine - quinidine Increases the effect of quinidine (source: Drug Bank )
cisapride - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
cisapride - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
cisapride - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
clarithromycin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
clarithromycin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
clomipramine - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
clomipramine - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
clomipramine - quinidine Quinidine barbiturate increases the effect of tricyclic antidepressant, clomipramine. (source: Drug Bank )
codeine - quinidine Quinidine decreases the analgesic effect of codeine (source: Drug Bank )
codeine - quinidine Quinidine decreases the analgesic effect of codeine (source: Drug Bank )
codeine - quinidine Quinidine decreases the analgesic effect of codeine (source: Drug Bank )
cyclosporine - quinidine The barbiturate, quinidine barbiturate, increases the effect of cyclosporine. (source: Drug Bank )
dantrolene - quinidine Quinidine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
desipramine - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
desipramine - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
desipramine - quinidine Quinidine barbiturate increases the effect of tricyclic antidepressant, desipramine. (source: Drug Bank )
dexamethasone - quinidine The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank )
dextromethorphan - quinidine Quinidine increases the toxicity of dextromethorphan (source: Drug Bank )
dextromethorphan - quinidine Quinidine increases the toxicity of dextromethorphan (source: Drug Bank )
digoxin - quinidine Quinine/quinidine increases the effect of digoxin (source: Drug Bank )
digoxin - quinidine Quinine/quinidine increases the effect of digoxin (source: Drug Bank )
diltiazem - quinidine Increases the effect and toxicity of quinidine (source: Drug Bank )
diltiazem - quinidine Increases the effect and toxicity of quinidine (source: Drug Bank )
diltiazem - quinidine Increases the effect and toxicity of quinidine (source: Drug Bank )
divalproex sodium - quinidine Divalproex sodium increases the effect of the barbiturate, quinidine barbiturate. (source: Drug Bank )
donepezil - quinidine Possible antagonism of action (source: Drug Bank )
donepezil - quinidine Possible antagonism of action (source: Drug Bank )
doxepin - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
doxepin - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
doxepin - quinidine Quinidine barbiturate increases the effect of tricyclic antidepressant, doxepin. (source: Drug Bank )
doxycycline - quinidine The anticonvulsant, quinidine barbiturate, decreases the effect of doxycycline. (source: Drug Bank )
erythromycin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
erythromycin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
felodipine - quinidine The barbiturate, quinidine barbiturate, decreases the effect of felodipine. (source: Drug Bank )
fludrocortisone - quinidine The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone. (source: Drug Bank )
folic acid - quinidine Folic acid decreases the effect of anticonvulsant, quinidine barbiturate. (source: Drug Bank )
fosphenytoin - quinidine The anticonvulsant, fosphenytoin, decreases the effect of quinidine. (source: Drug Bank )
galantamine - quinidine Possible antagonism of action (source: Drug Bank )
galantamine - quinidine Possible antagonism of action (source: Drug Bank )
gatifloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
gatifloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
gefitinib - quinidine The CYP3A4 inducer, quinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib. (source: Drug Bank )
grepafloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
grepafloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
griseofulvin - quinidine The barbiturate, quinidine barbiturate, decreases the effect of griseofulvin. (source: Drug Bank )
hydrocortisone - quinidine The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
imipramine - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
imipramine - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
imipramine - quinidine Quinidine barbiturate increases the effect of tricyclic antidepressant, imipramine. (source: Drug Bank )
itraconazole - quinidine The imidazole increases the effect and toxicity of quinidine (source: Drug Bank )
itraconazole - quinidine The imidazole increases the effect and toxicity of quinidine (source: Drug Bank )
ketoconazole - quinidine The imidazole increases the effect and toxicity of quinidine (source: Drug Bank )
ketoconazole - quinidine The imidazole increases the effect and toxicity of quinidine (source: Drug Bank )
ketoconazole - quinidine The imidazole increases the effect and toxicity of quinidine (source: Drug Bank )
levofloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
levofloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
levonorgestrel - quinidine Phenobarbital decreases the effect of levonorgestrel (source: Drug Bank )
Magnesium - quinidine The antiacid decreases the absorption of quindine (source: Drug Bank )
mesoridazine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
mesoridazine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
methadone - quinidine The barbiturate decreases the effect of methadone (source: Drug Bank )
methadone - quinidine The barbiturate, quinidine barbiturate, decreases the effect of methadone. (source: Drug Bank )
metoprolol - quinidine The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank )
metoprolol - quinidine The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank )
metronidazole - quinidine The barbiturate, quinidine barbiturate, decreases the effect of metronidazole. (source: Drug Bank )
moxifloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
moxifloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
nelfinavir - quinidine Nelfinavir increases the effect and toxicity of quinidine (source: Drug Bank )
nelfinavir - quinidine Nelfinavir increases the effect and toxicity of quinidine (source: Drug Bank )
nifedipine - quinidine Decreased quinidine effect, increased nifedipine effect (source: Drug Bank )
nifedipine - quinidine Decreased quinidine effect, increased nifedipine effect (source: Drug Bank )
nifedipine - quinidine Decreased quinidine effect, increased nifedipine effect (source: Drug Bank )
nortriptyline - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
nortriptyline - quinidine Quinidine increases the effect of tricyclic agent (source: Drug Bank )
nortriptyline - quinidine Quinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline. (source: Drug Bank )
ofloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
ofloxacin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
oxtriphylline - quinidine The barbiturate, quinidine barbiturate, decreases the effect of oxtriphylline. (source: Drug Bank )
phenobarbital - quinidine The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
phenobarbital - quinidine The anticonvulsant, phenobarbital, decreases the effect of quinidine. (source: Drug Bank )
phenytoin - quinidine The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
phenytoin - quinidine The anticonvulsant, phenytoin, decreases the effect of quinidine. (source: Drug Bank )
prednisolone - quinidine The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone. (source: Drug Bank )
prednisone - quinidine The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisone. (source: Drug Bank )
primidone - quinidine The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
primidone - quinidine The anticonvulsant, primidone, decreases the effect of quinidine. (source: Drug Bank )
procainamide - quinidine Quinidine increases the effect of procainamide (source: Drug Bank )
procainamide - quinidine Quinidine increases the effect of procainamide (source: Drug Bank )
propafenone - quinidine Quinidine increases the effect of propafenone (source: Drug Bank )
propafenone - quinidine Quinidine increases the effect of propafenone (source: Drug Bank )
propafenone - quinidine Quinidine increases the effect of propafenone (source: Drug Bank )
propranolol - quinidine The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank )
propranolol - quinidine The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank )
quinidine - acenocoumarol Quinine/quinidine increases the anticoagulant effect (source: Drug Bank )
quinidine - acenocoumarol Quinidine may increase the anticoagulant effect of acenocoumarol. (source: Drug Bank )
quinidine - amiloride Amiloride decreases the antiarrhythmic effect of quinidine (source: Drug Bank )
quinidine - amiloride Amiloride decreases the antiarrhythmic effect of quinidine (source: Drug Bank )
quinidine - amiodarone Amiodarone increases the effect of quinidine (source: Drug Bank )
quinidine - amiodarone Amiodarone increases the effect of quinidine (source: Drug Bank )
quinidine - amitriptyline Quinidine increases the effect of the tricyclic agent (source: Drug Bank )
quinidine - amitriptyline Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy. (source: Drug Bank )
quinidine - amobarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - amobarbital The anticonvulsant, amobarbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - anisindione Quinine/quinidine increases the anticoagulant effect (source: Drug Bank )
quinidine - anisindione Quinidine may increase the anticoagulant effect of anisindione. (source: Drug Bank )
quinidine - aprobarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - aprobarbital The anticonvulsant, aprobarbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - aripiprazole Quinidine increases the effect and toxicity of aripiprazole (source: Drug Bank )
quinidine - aripiprazole Quinidine increases the effect and toxicity of aripiprazole (source: Drug Bank )
quinidine - atazanavir Increased risk of cardiotoxicity/arrhythmias (source: Drug Bank )
quinidine - atazanavir Increased risk of cardiotoxicity/arrhythmias (source: Drug Bank )
quinidine - atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank )
quinidine - atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank )
quinidine - atracurium The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - atracurium The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - butabarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - butabarbital The anticonvulsant, butabarbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - butalbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - butalbital The anticonvulsant, butalbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - butethal The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - butethal The anticonvulsant, butethal, decreases the effect of quinidine. (source: Drug Bank )
quinidine - cimetidine Cimetidine increases the effect of quinidine (source: Drug Bank )
quinidine - cimetidine Cimetidine increases the effect of quinidine (source: Drug Bank )
quinidine - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - clarithromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - clarithromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - clomipramine Quinidine increases the effect of the tricyclic agent (source: Drug Bank )
quinidine - clomipramine Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy. (source: Drug Bank )
quinidine - codeine Quinidine decreases the analgesic effect of codeine (source: Drug Bank )
quinidine - codeine Quinidine decreases the analgesic effect of codeine (source: Drug Bank )
quinidine - desipramine Quinidine increases the effect of the tricyclic agent (source: Drug Bank )
quinidine - desipramine Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy. (source: Drug Bank )
quinidine - dextromethorphan Quinidine increases the toxicity of dextromethorphan (source: Drug Bank )
quinidine - dextromethorphan Quinidine increases the toxicity of dextromethorphan (source: Drug Bank )
quinidine - dicumarol Quinine/quinidine increases the anticoagulant effect (source: Drug Bank )
quinidine - dicumarol Quinidine may increase the anticoagulant effect of dicumarol. (source: Drug Bank )
quinidine - digitoxin Quinine/quinidine increases the effect of digoxin (source: Drug Bank )
quinidine - digitoxin Quinine/quinidine increases the effect of digoxin (source: Drug Bank )
quinidine - digoxin Quinine/quinidine increases the effect of digoxin (source: Drug Bank )
quinidine - digoxin Quinine/quinidine increases the effect of digoxin (source: Drug Bank )
quinidine - diltiazem Diltiazem increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - diltiazem Diltiazem increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - donepezil Possible antagonism of action (source: Drug Bank )
quinidine - donepezil Possible antagonism of action (source: Drug Bank )
quinidine - doxepin Quinidine increases the effect of the tricyclic agent (source: Drug Bank )
quinidine - doxepin Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if doxepin is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy. (source: Drug Bank )
quinidine - erythromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - erythromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - fosphenytoin The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - fosphenytoin The anticonvulsant, fosphenytoin, decreases the effect of quinidine. (source: Drug Bank )
quinidine - galantamine Possible antagonism of action (source: Drug Bank )
quinidine - galantamine Possible antagonism of action (source: Drug Bank )
quinidine - gallamine triethiodide The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - gallamine triethiodide The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - heptabarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - heptabarbital The anticonvulsant, heptabarbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - hexobarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - hexobarbital The anticonvulsant, hexobarbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - imipramine Quinidine increases the effect of the tricyclic agent (source: Drug Bank )
quinidine - imipramine Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy. (source: Drug Bank )
quinidine - itraconazole The imidazole increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - itraconazole The imidazole increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - ketoconazole The imidazole increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - ketoconazole The imidazole increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - Magnesium The antacid increases the effect of quinidine (source: Drug Bank )
quinidine - Magnesium The antacid increases the effect of quinidine (source: Drug Bank )
quinidine - mesoridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - mesoridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - methohexital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - methohexital The anticonvulsant, methohexital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - methylphenobarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - methylphenobarbital The anticonvulsant, methylphenobarbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - metocurine The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - metocurine The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - moxifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - moxifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - nelfinavir Nelfinavir increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - nelfinavir Nelfinavir increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - nifedipine Decreased quinidine effect, increased nifedipine effect (source: Drug Bank )
quinidine - nifedipine Decreased quinidine effect, increased nifedipine effect (source: Drug Bank )
quinidine - nortriptyline Quinidine increases the effect of the tricyclic agent (source: Drug Bank )
quinidine - nortriptyline Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy. (source: Drug Bank )
quinidine - ofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - ofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - pancuronium The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - pancuronium The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - pentobarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - pentobarbital The anticonvulsant, pentobarbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - phenobarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - phenobarbital The anticonvulsant, phenobarbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - phenytoin The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - phenytoin The anticonvulsant, phenytoin, decreases the effect of quinidine. (source: Drug Bank )
quinidine - posaconazole Contraindicated co-administration (source: Drug Bank )
quinidine - posaconazole Contraindicated co-administration (source: Drug Bank )
quinidine - primidone The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - primidone The anticonvulsant, primidone, decreases the effect of quinidine. (source: Drug Bank )
quinidine - procainamide Quinidine increases the effect of procainamide (source: Drug Bank )
quinidine - procainamide Quinidine increases the effect of procainamide (source: Drug Bank )
quinidine - propafenone Quinidine increases the effect of propafenone (source: Drug Bank )
quinidine - propafenone Quinidine increases the effect of propafenone (source: Drug Bank )
quinidine - protriptyline Quinidine increases the effect of the tricyclic agent (source: Drug Bank )
quinidine - protriptyline Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy. (source: Drug Bank )
quinidine - quinidine The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - quinidine The anticonvulsant, quinidine. barbiturate, decreases the effect of quinidine. (source: Drug Bank )
quinidine - quinupristin This combination presents an increased risk of toxicity (source: Drug Bank )
quinidine - quinupristin This combination presents an increased risk of toxicity (source: Drug Bank )
quinidine - ranolazine Possible additive effect on QT prolongation (source: Drug Bank )
quinidine - ranolazine Possible additive effect on QT prolongation (source: Drug Bank )
quinidine - rifampin Rifampin decreases the effect of quinidine (source: Drug Bank )
quinidine - rifampin Rifampin decreases the effect of quinidine (source: Drug Bank )
quinidine - ritonavir Ritonavir increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - ritonavir Ritonavir increases the effect and toxicity of quinidine (source: Drug Bank )
quinidine - rivastigmine Possible antagonism of action (source: Drug Bank )
quinidine - rivastigmine Possible antagonism of action (source: Drug Bank )
quinidine - salicylate-magnesium The antacid increases the effect of quinidine (source: Drug Bank )
quinidine - secobarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - secobarbital The anticonvulsant, secobarbital, decreases the effect of quinidine. (source: Drug Bank )
quinidine - sodium The antacid increases the effect of quinidine (source: Drug Bank )
quinidine - sodium The antacid increases the effect of quinidine (source: Drug Bank )
quinidine - sodium bicarbonate The antacid increases the effect of quinidine (source: Drug Bank )
quinidine - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - succinylcholine The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - succinylcholine The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - talbutal The anticonvulsant decreases the effect of quinidine (source: Drug Bank )
quinidine - talbutal The anticonvulsant, talbutal, decreases the effect of quinidine. (source: Drug Bank )
quinidine - telithromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - telithromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - trimipramine Quinidine increases the effect of the tricyclic agent (source: Drug Bank )
quinidine - trimipramine Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, trimipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy. (source: Drug Bank )
quinidine - vecuronium The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - vecuronium The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank )
quinidine - verapamil Verapamil increases the effect of quinidine (source: Drug Bank )
quinidine - verapamil Verapamil increases the effect of quinidine (source: Drug Bank )
quinidine - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - warfarin Quinine/quinidine increases the anticoagulant effect (source: Drug Bank )
quinidine - warfarin Quinidine may increase the anticoagulant effect of warfarin. (source: Drug Bank )
quinidine - ziprasidone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - ziprasidone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinupristin - quinidine This combination presents an increased risk of toxicity (source: Drug Bank )
ranolazine - quinidine Possible additive effect on QT prolongation (source: Drug Bank )
rifampin - quinidine Rifampin decreases the effect of quinidine (source: Drug Bank )
rifampin - quinidine Rifampin decreases the effect of quinidine (source: Drug Bank )
tadalafil - quinidine Quinidine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity. (source: Drug Bank )
tamoxifen - quinidine Quinidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank )
tamoxifen - quinidine Quinidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank )
tamsulosin - quinidine Quinidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinidine is initiated, discontinued, or dose changed. (source: Drug Bank )
tamsulosin - quinidine Quinidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinidine is initiated, discontinued, or dose changed. (source: Drug Bank )
telithromycin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
telithromycin - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
teniposide - quinidine The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
terfenadine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
terfenadine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
theophylline - quinidine The barbiturate decreases the effect of theophylline (source: Drug Bank )
theophylline - quinidine The barbiturate, quinidine barbiturate, decreases the effect of theophylline. (source: Drug Bank )
thiopental - quinidine Thiopental may increase the metabolism and clearance of Quinidine. Monitor for decreased therapeutic effect of Quinidine if Thiopental is initiated. (source: Drug Bank )
thiopental - quinidine Thiopental may increase the metabolism and clearance of Quinidine. Monitor for decreased therapeutic effect of Quinidine if Thiopental is initiated. (source: Drug Bank )
thioridazine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
thioridazine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
thioridazine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
tiagabine - quinidine The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
tipranavir - quinidine Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Quinidine. Concomitant therapy is contraindicated. (source: Drug Bank )
tolterodine - quinidine Quinidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank )
tolterodine - quinidine Quinidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank )
topotecan - quinidine The p-glycoprotein inhibitor, Quinidine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. (source: Drug Bank )
toremifene - quinidine Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
tramadol - quinidine Quinidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Quinidine may decrease the effect of Tramadol by decreasing active metabolite production. (source: Drug Bank )
trazodone - quinidine The CYP3A4 inhibitor, Quinidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
trazodone - quinidine The CYP3A4 inhibitor, Quinidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
triamcinolone - quinidine The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone. (source: Drug Bank )
trimipramine - quinidine Additive QTc-prolonging effects may occur, increasing the risk of serious cardiac arrhythmias. Quinidine, a CYP2D6/CYP3A4 inhibitor, may also inhibit the metabolism of Trimipramine, a CYP2D6/CYP3A4 substrate. Monitor for signs of cardiac arrhythmias and for changes in Trimipramine efficacy and toxicity if Quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
vardenafil - quinidine Quinidine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil. (source: Drug Bank )
venlafaxine - quinidine Quinidine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Quinidine is initiated, discontinued, or dose changed. (source: Drug Bank )
verapamil - quinidine Concurrent therapy may result in increased serum levels of both agents. Both agents are CYP3A4 inhibitors and substrates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of the agent if the other is initiated, discontinued or dose changed. (source: Drug Bank )
vincristine - quinidine Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
vinorelbine - quinidine Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - quinidine Voriconazole may increase the serum concentration of quinidine likely by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the serum concentration and toxic effects of quinidine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
vorinostat - quinidine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
ziprasidone - quinidine Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. (source: Drug Bank )
zolpidem - quinidine Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
zonisamide - quinidine Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
zopiclone - quinidine Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if quinidine is initiated, discontinued or dose changed. (source: Drug Bank )
zuclopenthixol - quinidine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Quinidine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if quinidine is initiated, discontinued or dose changed. (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to quinidine: 29

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics. 2015. Duconge Jorge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of pro-arrhythmic adverse drug reactions. British journal of clinical pharmacology. 2014. Petropoulou Evmorfia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PloS one. 2013. Behr Elijah R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An Allosteric Mechanism for Drug Block of the Human Cardiac Potassium Channel KCNQ1. Molecular pharmacology. 2012. Yang Tao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes. Circulation. Cardiovascular genetics. 2011. Kääb Stefan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced long QT syndrome. Pharmacological reviews. 2010. Kannankeril Prince, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. British journal of pharmacology. 2010. Yang Tao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenetics and genomics. 2010. Agrawal Vishal, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clinical pharmacology and therapeutics. 2009. Anthony M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP2D6 polymorphism on pharmacokinetics of a novel ACAT inhibitor, pactimibe and its unique metabolite, R-125528. International journal of clinical pharmacology and therapeutics. 2008. Kotsuma M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Molecular pharmacology. 2008. Perrin Mark J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug metabolism and disposition: the biological fate of chemicals. 2007. Shen Hongwu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart rhythm : the official journal of the Heart Rhythm Society. 2005. Kannankeril Prince J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British journal of clinical pharmacology. 2004. Hutchinson Mark R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. American journal of therapeutics. 2003. Cubeddu Luigi X. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharmaceutical research. 2002. Härtter Sebastian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4'- and 10-hydroxywarfarin. Drug metabolism and disposition: the biological fate of chemicals. 2001. Ngui J S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000. Haritos V S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation. 1999. Priori S G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The family of Na+/Cl- neurotransmitter transporters. Journal of neurochemistry. 1998. Nelson N. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clinical pharmacology and therapeutics. 1997. Madsen H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. Neuropsychobiology. 1992. Eap C B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical pharmacology and therapeutics. 1991. Brøsen K, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
53489-459-02
DrugBank:
DB00908
ChEBI:
28593
KEGG Compound:
C06527
PubChem Compound:
441074
PubChem Substance:
46505356
8758
IUPHAR Ligand:
2342
Drugs Product Database (DPD):
497525
ChemSpider:
389880
Therapeutic Targets Database:
DAP000515

Clinical Trials

These are trials that mention quinidine and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.